News & Updates

Show Multimedia Only

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

19 Aug 2025

The combination of sintilimab plus axitinib demonstrates encouraging antitumour activity in patients with fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) while having a manageable safety profile, according to a phase II study conducted in China.

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

19 Aug 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

New drug applications approved by US FDA as of 1-15 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

14 Aug 2025

Concurrent administration of sacituzumab govitecan and radiotherapy is well tolerated and does not lead to increased toxicity in patients with metastatic breast cancer, a study has shown.

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

14 Aug 2025

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

14 Aug 2025 by

The E-STOP trial presented at ESHRE 2025 supports early antibiotic suspension in paediatric patients with cancer and febrile neutropenia (FN).

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

14 Aug 2025

Peg-filgrastim reduces neutropenia in children with solid tumours

13 Aug 2025

The incidence of febrile neutropenia (FN) is significantly lesser in children with solid tumours receiving pegylated filgrastim as primary prophylaxis following chemotherapy than in those assigned to filgrastim alone, reports a study. Moreover, no adverse events attributed to the study drug have been observed.

Peg-filgrastim reduces neutropenia in children with solid tumours

13 Aug 2025

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. Patients are increasingly more aware of new and different treatment options and are seeking therapies that align with their personal values. As survival outcomes continue to improve, shared decision-making (SDM) plays a vital role in individualising care by integrating clinical evidence with what matters most to each individual. This article explores how SDM can support patient-centred care, drawing on insights from Professor James Yang and patient advocate Mark Brooke.

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

Vorasidenib prevents seizures in mIDH1/2 gliomas

12 Aug 2025 by

Patients with grade 2 isocitrate dehydrogenase 1 or 2 mutant (mIDH1/2) gliomas receiving vorasidenib experience fewer seizure activities than those on placebo, as shown by the results of the INDIGO study.

Vorasidenib prevents seizures in mIDH1/2 gliomas

12 Aug 2025

Adiposity levels may predict CRC risk

11 Aug 2025

High adiposity levels are associated with the risk of colorectal cancer (CRC), suggest the results of a systematic review. However, standardization is necessary to improve understanding of the link between CRC and adiposity to enable comparisons across papers.

Adiposity levels may predict CRC risk

11 Aug 2025

DeLLphi-304: Tarlatamab bests SoC chemo as 2L treatment for SCLC

07 Aug 2025 by

Tarlatamab was associated with significant improvements in overall survival (OS), progression-free survival (PFS) and patient-reported outcomes (PROs) vs standard-of-care (SoC) chemotherapy in patients with small-cell lung cancer (SCLC) undergoing second-line (2L) therapy, according to the primary analysis of the phase III DeLLphi-304 study presented at ASCO 2025.

DeLLphi-304: Tarlatamab bests SoC chemo as 2L treatment for SCLC

07 Aug 2025

Scheduled lorazepam-based regimens superior to haloperidol alone for agitated delirium at end of life

06 Aug 2025 by

Proactive use of scheduled lorazepam or lorazepam plus haloperidol is superior to haloperidol alone in managing refractory agitated delirium in patients with advanced cancer in the palliative care setting, according to results of a multicentre randomized clinical trial (RCT) conducted in Taiwan and the US.

Scheduled lorazepam-based regimens superior to haloperidol alone for agitated delirium at end of life

06 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

Peg-filgrastim reduces neutropenia in children with solid tumours

Peg-filgrastim reduces neutropenia in children with solid tumours

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Vorasidenib prevents seizures in mIDH1/2 gliomas

Vorasidenib prevents seizures in mIDH1/2 gliomas

Adiposity levels may predict CRC risk

Adiposity levels may predict CRC risk

DeLLphi-304: Tarlatamab bests SoC chemo as 2L treatment for SCLC

DeLLphi-304: Tarlatamab bests SoC chemo as 2L treatment for SCLC

Scheduled lorazepam-based regimens superior to haloperidol alone for agitated delirium at end of life

Scheduled lorazepam-based regimens superior to haloperidol alone for agitated delirium at end of life